PRESSR: The value of the diabetes treatment devices market in the UAE will rise to more than 781 million dirhams by 2030

The diabetes treatment devices market in the UAE depends on several factors that include: the widespread prevalence of diabetes, rapid adoption of innovative products, increasing research and development initiatives, and increasing focus on preventive care.
Arab Health 2024 hosts some of the most prominent expert speakers as part of a conference dedicated to diabetes, and showcases a range of advanced products to address the impact of “diabetes” in the region.
The 49th edition of Arab Health will be held at the Dubai World Trade Center from January 29 to February 1, 2024.

Dubai, United Arab Emirates: Arab Health 2024, the largest healthcare industry event in the Middle East, will highlight the growing importance of diabetes treatment in the UAE and the wider MENA region by showcasing the latest technologies and devices used to combat the disease. In addition to hearing insights from leading industry experts from Khalifa University in Abu Dhabi, the Sultan Bin Abdulaziz Humanitarian City in Riyadh, and Kuwait University in Kuwait City.

According to the latest statistics from Insights 10, a market research company, the value of the diabetes treatment devices market in the UAE reached more than 418 million AED in 2022, and this number is expected to reach more than 781 million AED in 2030, which confirms In turn, a compound annual growth rate of up to 8.20% will occur during the expected period.

Several factors contribute to the growth of the device market, most notably the high prevalence of diabetes in the region. According to Insights 10 statistics, 1.19 million residents in the United Arab Emirates have been diagnosed with diabetes as of 2022, equivalent to about 18.9% of the number. Total population of the UAE.

Moreover, data from the International Diabetes Federation, the organizing body for World Diabetes Day, which takes place tomorrow, Tuesday, November 14, indicates that 73 million people in the Middle East and North Africa region have diabetes, and the number is expected to rise by 87% to more than 135. million people by 2045.

The main reason that diabetes in the UAE went from an epidemic to a pandemic last year is to highlight the incidence of diabetes even more by screening the 43 million residents in the UAE who suffer from impaired glucose tolerance, which means that their blood sugar level rises. Beyond normal levels, but not high enough levels to warrant a diagnosis of diabetes.

On this occasion, Ross Williams, Director of the Arab Health Exhibition and Conference at Informa Markets, said: “We are committed to playing a pivotal role in promoting the discussion about diabetes by bringing together global experts and providing an ideal platform for exchanging ideas, researching and developing innovative solutions, and many exhibitors will be present this year.” “By showcasing the latest technologies and vital treatments to reduce diabetes rates in the UAE and across the Middle East, empowering global health is at the heart of what we do at Arab Health and is crucial in the fight against diabetes and improving the lives of countless individuals.”

Several different factors contribute to the market drivers of the rising value of diabetes treatment devices in the region, most notably the rapid adoption of new products, increased research and development, and increased awareness of diabetes within the region. A range of government initiatives and awareness programs are expected to boost growth, as well as demand for Screening and monitoring devices, which in turn simplifies patient management.

Arab Health 2024 will host a conference dedicated to diabetes from January 31 to February 1. The conference will include an elite group of high-level speakers, most notably: Dr. Laith Al-Rubaie, Consultant in Gastroenterology and Hepatology at Healthpoint Hospital, and Professor at Khalifa University, Abu Dhabi; Dr. Maha Barakat, Director General of the Fakhr Al Watan Office and Senior Advisor to Mubadala Company in Abu Dhabi, and Professor Dr. Khaled Al-Rubaian, Director of the Research and Scientific Center at the Sultan bin Abdulaziz Humanitarian City in Riyadh; Dr. Ibaa Al-Uzairi, Medical Director and Consultant in Endocrinology and Nutrition at Kuwait University in Kuwait City, and Dr. Ahmed Al-Laboudi, Consultant in Endocrinology and Diabetes at the Imperial College London Diabetes Centre.

Through discussion sessions, experts will shed light on the standards of medical care for patients with diabetes 2024, diabetes and intestines, the diabetes tsunami in the Gulf countries: size, damage and financial drain, type 1 diabetes, obesity and the role of adjuvant treatment.

Several companies, including New Country Healthcare (vitamins for diabetics), Prahem Laboratories and Iraqi Pharma, will showcase new medicines and technologies as they seek to support diabetes management globally.

Through Arab Health 2024, medical specialists and professionals will be able to attend 10 continuing medical education conferences in the areas of: comprehensive radiology, surgery, emergency medicine, critical care, diabetes, obstetrics and gynecology, orthopedics, quality management, public health, infection control, and central supply sterilization management.

The 2024 edition of Arab Health will see a fee charged for visitors to attend, ensuring the continuation of meaningful work and learning opportunities, as entry will be free for everyone who registers before January 3, 2024. After that, the cost will be AED 100 and AED 200 for those who register. At the event site.

Arab Health 2024 will be held with the support of a group of government agencies, including: the Ministry of Health and Community Protection in the United Arab Emirates, the Government of Dubai, the Dubai Health Authority, the Department of Health, the Emirates Health Services Corporation, and the Dubai Healthcare City Authority.

#Corporate data
- I finish -

About Arab Health Exhibition and Conference:

The Arab Health Exhibition and Conference, organized by Informa Markets, is considered the largest healthcare event in the Middle East. The exhibition was held for the first time 48 years ago, becoming a platform for the world’s major manufacturers, wholesalers and distributors to meet with the medical and scientific communities in the Middle East.

Arab Health Conference is known for providing the highest quality Continuing Medical Education (CME) programs for medical professionals in the region.

Arab Health 2024 Exhibition and Conference will be held from January 29 to February 1, 2024 at the Dubai World Trade Center in Dubai, United Arab Emirates.

Disclaimer regarding the content of press releases
The content of these press releases is provided by an external provider. We do not accept any responsibility or have permission to control such content. This content is provided on an 'as is' and 'as available' basis and has not been edited in any way. Neither we nor our affiliates will be responsible for ensuring the accuracy, endorsement or completeness of the opinions, views, information or materials contained in such content.
Press releases are provided for informational purposes only; The content does not suggest any advice on legal, investment or tax aspects or any opinions on the suitability, value or profitability of any particular portfolio or investment strategy. Neither we nor our affiliates will be liable for any errors or inaccuracies in the Content, or for any actions you take in reliance on that Content. You expressly agree and acknowledge that you bear full responsibility for the use of the information contained in these press releases.
To the extent permitted by applicable law, Refinitiv, its parent, subsidiaries, affiliates, and their respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors (collectively the “Refinitiv Parties”) will have no liability (either jointly or individually) to you. For any direct, indirect, consequential, special, incidental, punitive or exemplary damages; This includes, but is not limited to: loss of profits, loss of savings or revenue, whether due to negligence, tort, contract or other theories of liability, even if the Refinitiv Parties have been advised of the possibility of any such damages and losses or could have foreseen them. Actually happening.

ZAWYA 2023 ©

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.